1191O MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy
Year: 2021
Type: article
Source: Annals of Oncology
Institutions: University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Beverly Hills Cancer Center, Henry Ford Health, Vanderbilt University, Vanderbilt-Ingram Cancer Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Virginia Cancer Specialists, Masonic Cancer Center, Oncology Hematology Care, Rocky Mountain Cancer Centers, University of California, Los Angeles, The University of Texas MD Anderson Cancer Center, Mirati Therapeutics (United States), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3203988497